The Optic Neuritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Optic Neuritis: An Overview
The American Academy of Ophthalmology defined Optic Neuritis (ON) as the swelling of the eye’s optic nerve. The optic nerve carries light signals from the back of the eye to the brain so that a person can see. A person cannot see clearly if the optic nerve is swollen, damaged or is infected. It is an acute rare disorder that usually occurs in one eye, and is characterized by symptoms including blurring of vision, a loss of part or all of central vision, reduced colour vision, and dimness of vision. Most patients with ON have eye pain which characteristically worsens with movement of the eye.
Optic Neuritis is most common among adults, aged 20 to 40 years, and its symptoms generally improve in 80 per cent of patients over a few weeks. More females are affected than males and approximately five out of every one-hundred thousand people are affected by Optic Neuritis every year [Thomas C. Weiss et al., 2018].
Optic Neuritis Market Key Facts
-
As per The Transverse Myelitis Association, Optic Neuritis is a rare condition with an estimated annual incidence of 6.4 per 100,000 cases in the population in the United States. Also, the occurrence of Optic Neuritis tends to be the highest in populations located in higher latitudes (in the northern US and Western Europe) and is the lowest in regions closer to the equator.
-
In 15%-20% of people who eventually develop Multiple Sclerosis, Optic Neuritis is their first symptom. The risk of developing Multiple Sclerosis following one episode of Optic Neuritis is approximately 50% within 15 years of any first episode of Optic Neuritis.
-
Literature review suggests that from almost all parts of the world, regions with the highest incidence include northern Europe and the middle part of North America. Also, Optic Neuritis is reported to have an incidence of 1-5 cases per 100,000/year; the higher the latitude higher was found to be the incidence of Optic Neuritis.
Key Benefits of Optic Neuritis Market Report
-
The report provides an in-depth analysis of Optic Neuritis Market Size and Share till 2032 in the 7MM.
-
The report will help in developing business strategies by understanding the Optic Neuritis Market Trends, key players, and ongoing developments activities, that shape and drive the market growth in the upcoming years.
-
It covers Optic Neuritis current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.
-
The report provides a detailed assessment of the Optic Neuritis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Optic Neuritis market size is expected to increase during the forecast period owing to the launch of upcoming therapies and the active participation of the key companies in the domain.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Optic Neuritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Optic Neuritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/optic-neuritis-market
Optic Neuritis Epidemiology
The epidemiology section covers insights about the historical and current Optic Neuritis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Optic Neuritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Optic Neuritis market or expected to get launched in the market during the study period. The analysis covers Optic Neuritis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Optic Neuritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Optic Neuritis Therapeutics Analysis
Globally some of the key companies are actively working to develop new therapies for the treatment of Optic Neuritis. The launch of the emerging therapies is expected to transform the Optic Neuritis Therapeutics Landscape.
Optic Neuritis Companies:
-
Questcor
-
Biogen
-
Mitochon Pharmaceuticals
-
Noveome Biotherapeutics
And many more.
Optic Neuritis Therapies Covered in the Report Include:
-
Opicinumab
-
MP101
-
H.P. Acthar Gel (repository corticotropin) Injection
And others
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/optic-neuritis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Optic Neuritis Competitive Intelligence Analysis
4. Optic Neuritis Market Overview at a Glance
5. Optic Neuritis Disease Background and Overview
6. Optic Neuritis Patient Journey
7. Optic Neuritis Epidemiology and Patient Population
8. Optic Neuritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Optic Neuritis Unmet Needs
10. Key Endpoints of Optic Neuritis Treatment
11. Optic Neuritis Marketed Products
12. Optic Neuritis Emerging Therapies
13. Optic Neuritis Seven Major Market Analysis
14. Attribute Analysis
15. Optic Neuritis Market Outlook (7 major markets)
16. Optic Neuritis Access and Reimbursement Overview
17. KOL Views on the Optic Neuritis Market.
18. Optic Neuritis Market Drivers
19. Optic Neuritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/optic-neuritis-market
Latest Healthcare Report by DelveInsight
Fatigue is one of the common problems and debilitating symptoms in cancer patients. It is observed that a majority of patients experience some level of fatigue during their course of treatment. However, to overcome the Cancer Related Fatigue, globally several key companies are working in the therapeutics domain.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/